Effects of choline alfoscerate on cognitive function and quality of life in type 2 diabetes: A double‐blind, randomized, placebo‐controlled trial
Choline alfoscerate 1200 mg once daily treatment showed marginal improvement in cognitive function in T2DM patients with mild cognitive impairment at 6 months but leading to significance at 12 months compared to placebo, suggesting its potential as an adjunct therapy for managing early cognitive decline.
Authors
- Soo Kyung Lim (ORCID: https://orcid.org/0000-0002-4137-1671)
- Young Ho Park (ORCID: https://orcid.org/0000-0002-2756-1786)
- Minji Sohn (ORCID: https://orcid.org/0000-0001-6276-0492)
Institutions
- Seoul National University Bundang Hospital (KR)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2024-12-20
- DOI
- https://doi.org/10.1111/dom.16131
- Citations
- 1
- Primary Topic
- Neurological Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.25
Funders
- Daewoong Pharmaceutical Company